骨疏康胶囊对经皮球囊椎体后凸成形术后患者骨密度、骨代谢及生活质量的影响OA

Objective:To observe the effects of Gushukang Capsules(Osteoporosis Relieving Capsules)on bone min-eral density(BMD),bone metabolism,and quality of life in patients with osteoporotic vertebral compression fracture(OVCF)after percutaneous kyphoplasty(PKP).Methods:This study enrolled 80 OVCF patients who underwent PKP sur-gery at the Second Affiliated Hospital of Anhui University of Chinese Medicine from January 2023 to March 2025.The par-ticipants were randomly assigned to a treatment group and a control group using a random number table,with 40 patients in each group.Patients in the control group received basic treatment starting from the first postoperative week,consisting of oral calcium carbonate and vitamin D3 tablets(1 tablet/time,twice daily)combined with calcitriol soft capsules(1 capsule/time,twice daily).Patients in the treatment group received additional oral Gushukang Capsules(4 capsules/time,twice daily)on top of the control group's treatment.Both groups were treated for 6 months.BMD of the lumbar spine and femoral neck,serum levels of osteocalcin(OC)and C-terminal telopeptide of type I collagen(S-CTX)were evaluated before and after 6 months of treatment.Quality of life was assessed using the 36-Item Short Form Health Survey(SF-36),pain intensity was quantified using the Visual Analogue Scale(VAS),and lumbar function status was evaluated using the Oswestry Disability Index(ODI)before treatment,after 3 months,and after 6 months of treatment.Results:Before treatment,there were no statistically significant differences between the two groups in BMD of the lumbar spine and femoral neck,serum levels of OC and S-CTX,or scores on the SF-36,VAS,and ODI scales(P>0.05),indicating comparability.After 6 months of intervention,BMD of the lumbar spine and femoral neck and SF-36 scores significantly increased from baseline,while VAS and ODI scores significantly decreased in both groups(P<0.05).In the treatment group,OC levels significantly increased and S-CTX levels significantly decreased from baseline(P<0.05).In the control group,there was no statistically significant difference in OC and S-CTX levels before and after treatment(P>0.05).Inter-group comparison results showed that after 3 months of treat-ment,the treatment group's SF-36,VAS,and ODI scores were significantly better than those of the control group(P<0.05).After 6 months of treatment,the treatment group's BMD of the lumbar spine and femoral neck,serum levels of OC and S-CTX,and scores on the SF-36,VAS,and ODI scales were all significantly better than those of the control group(P<0.05).Conclusion:In OVCF patients after PKP,adjuvant therapy with Gushukang Capsules combined with standard anti-osteoporosis treatment can significantly increase BMD levels,improve bone metabolic homeostasis,effectively alleviate pain symptoms,and promote motor function recovery,thereby significantly improving quality of life.